Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out barbiturate exposure. For follow-up testing of a presumptive result, Barbiturates, Urine Quantitative (2012213) is preferred.
Qualitative Enzyme Immunoassay/Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
New York DOH Approval Status
Transfer 4.0 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 2.0 mL)
Breast milk. Pharmaceutical preparation.
Ambient: 1 week; Refrigerated: 1 month; Frozen: 1 month
Screen cutoff concentration: 200 ng/mL
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
If the specimen screens positive, then Confirmation/Quantitation by GC-MS and/or LC-MS/MS (ARUP test code 2012213) will be added to confirm result. Additional charges apply.
80307; if reflexed, add 80345 (Reflexed Alt Code: G0480 )
|Component Test Code*||Component Chart Name||LOINC|
|0092196||Barbiturates, Urn, Screen||19270-8|
|2012212||Screen, Urine Interpretation||54247-2|
- Pain Management
- Pain Management, Barbiturates, Quantitative, with medMatch, Urine
- Pain Management, Barbiturates, with Confirmation with medMatch, Urine